Core Viewpoint - The stock of Sino Biopharmaceutical-B (02591) has experienced a significant decline of over 25% following its inclusion in the Hong Kong Stock Connect, with a current trading price of HKD 32.9 and a trading volume of HKD 19.69 million [1] Group 1: Stock Performance - Sino Biopharmaceutical-B's stock fell more than 14% after being included in the Hong Kong Stock Connect and has continued to decline, with a total drop of 25% [1] - As of the latest update, the stock is down 12.73% at HKD 32.9, with a trading volume of HKD 19.69 million [1] Group 2: Regulatory Changes - The Shanghai and Shenzhen Stock Exchanges announced adjustments to the constituent stocks of the Hang Seng Composite MidCap Index, resulting in the inclusion of Sino Biopharmaceutical in the Hong Kong Stock Connect, effective from December 8, 2025 [1] Group 3: Product Development - Sino Biopharmaceutical announced that its self-developed long-acting GLP-1 receptor agonist, Ispaglutide α (Yinuo Qing®), has been officially included in the National Medical Insurance Drug List for 2025, set to take effect on January 1, 2026 [1] - Ispaglutide α (Yinuo Qing®) is recognized as a domestically produced long-acting GLP-1 receptor agonist [1]

Major Events - GuoXia Technology (02655) plans to conduct an IPO from December 8 to December 11, offering 33.85 million H-shares and introducing cornerstone investors such as Huikai Hong Kong [1] - Basilea Pharmaceutica AG (02616) has its drug Pujihua® (Pralsetinib Capsules) included in the National Medical Insurance Directory for 2025 [1] - Four Seasons Pharmaceutical (00460) sees its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Shanghai Pharmaceuticals (02607) successfully negotiates and includes Amisulpride Orally Disintegrating Tablets in the National Medical Insurance Directory [1] - Hansoh Pharmaceutical (03692) has its innovative drug Amelotex® approved for two new indications in the updated 2025 National Medical Insurance Directory [1] - Xiansheng Pharmaceutical (02096) sees EnzeShu® and EnDu® included in the updated National Medical Insurance Drug List [1] - Hutchison China MediTech (00013) has its drug Tazverik® included in the first edition of the National Commercial Health Insurance Innovative Drug List [1] - XuanZhu Biotechnology (02575) has its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Yino Pharmaceutical (02591) has its H-shares included in the list of eligible securities for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect [1] - China Metallurgical Group (01618) and its subsidiaries plan to sell non-core business assets for approximately 60.68 billion yuan, focusing on core businesses in metallurgical engineering, non-ferrous metals, and mining engineering [1] - Cambridge Technology (06166) intends to invest a total of 405 million yuan to acquire and subscribe for shares in the Yangzhong Happiness Home Venture Capital Partnership Fund [1] Operating Performance - Dongfeng Motor Group (00489) reports cumulative automobile sales of 1.697 million units in the first 11 months, a year-on-year decrease of approximately 0.3% [2] - New天绿色能源 (00956) achieves a cumulative power generation of 1,336.89 million MWh in the first 11 months, an increase of 8.04% year-on-year [2] - Longyuan Power (00916) reports a cumulative power generation of approximately 6,909.64 million MWh in the first 11 months, a year-on-year growth of 0.41% [2] - Baolong Real Estate (01238) records a total contract sales of approximately 6.666 billion yuan in the first 11 months, a year-on-year decline of 43.2% [2]

Market Overview - The Hong Kong stock market faced pressure, with the Hang Seng Index dropping over 1%, closing at 25,965.36 points, down 1.23% or 319.72 points, with a total turnover of HKD 2,062.3 million [1] - The Hang Seng China Enterprises Index fell by 1.25% to 9,083.53 points, while the Hang Seng Tech Index remained flat at 5,662.55 points [1] Blue Chip Performance - Baidu Group-SW (09888) led blue-chip stocks, rising 3.45% to HKD 125.8, contributing 8.38 points to the Hang Seng Index [2] - Other notable performers included SMIC (00981) up 2.94%, China Ping An (02318) up 2.15%, while China Construction Bank (00939) fell 4.01%, dragging the index down by 54.39 points [2] Sector Highlights - Large tech stocks generally declined, with Alibaba down over 1% and Tencent down 0.82% [3] - Chinese brokerage stocks rose against the trend, with Huatai Securities (06886) up 5.17% and GF Securities (01776) up 3.1% [3] - The light communication sector saw significant gains, with Huiju Technology rising over 7% [4] - Lithium stocks mostly increased, with Ganfeng Lithium (01772) up 6.95% and CATL (03750) up 3.28% [5] Regulatory Developments - The Chairman of the China Securities Regulatory Commission (CSRC) emphasized the need to accelerate the development of top-tier investment banks and institutions, indicating a potential easing of regulations for quality institutions [4] - The CSRC plans to optimize risk control indicators and moderately open up capital space and leverage limits, which could benefit leading brokerages [4] New Listings and Stock Movements - Two new stocks were listed, with Zhuoyue Ruixin (02687) surging 87.26% and Naxinwei (02676) declining 4.31% [7] - Restructured Energy (02570) faced a significant drop of 27.33% on its first trading day after the lock-up period ended [8] - Silver Pharma-B (02591) saw a decline of 14.32% following its inclusion in the Hong Kong Stock Connect [9] - Sutech (02498) performed well, rising 5.23% after securing a major order from FAW Toyota [10] Pharmaceutical Sector Updates - The National Healthcare Security Administration announced the addition of 114 new drugs to the 2025 National Medical Insurance Drug List, with a success rate of 88%, up from 76% in 2024 [6]

Market Overview - The Hong Kong stock market faced pressure, with the Hang Seng Index dropping over 1%, closing at 25,965.36 points, down 1.23% or 319.72 points, with a total turnover of HKD 206.23 billion [1] - The Hang Seng China Enterprises Index fell by 1.25% to 9,083.53 points, while the Hang Seng Tech Index remained flat at 5,662.55 points [1] Blue Chip Performance - Baidu Group-SW (09888) led blue-chip stocks, rising 3.45% to HKD 125.8, contributing 8.38 points to the Hang Seng Index [2] - Other notable performers included SMIC (00981) up 2.94% and China Ping An (02318) up 2.15%, while China Construction Bank (00939) fell 4.01%, dragging the index down by 54.39 points [2] Sector Highlights - Major technology stocks generally declined, with Alibaba down over 1% and Tencent down 0.82% [3] - Chinese brokerage stocks rose against the trend, with Huatai Securities (06886) up 5.17% and GF Securities (01776) up 3.1% [3][4] - The light communication sector saw significant gains, with Huiju Technology (01729) rising 7.65% [4] - Lithium stocks mostly increased, with Ganfeng Lithium (01772) up 6.95% and CATL (03750) up 3.28% [5] Regulatory Developments - The Chairman of the China Securities Regulatory Commission (CSRC) emphasized the need to accelerate the development of top-tier investment banks and institutions, indicating a potential easing of regulations for quality institutions [4] - The CSRC plans to optimize risk control indicators and open up capital space and leverage limits [4] New Drug Listings - The National Healthcare Security Administration announced the addition of 114 new drugs to the 2025 National Medical Insurance Drug List, with a success rate of 88%, significantly higher than the previous year's 76% [6] New Listings and Stock Movements - New listings included Zhuoyue Ruixin (02687), which surged 87.26% to HKD 126.4, while Naxin Micro (02676) fell 4.31% [7] - Restructured Energy (02570) saw a significant drop of 27.33% on its first trading day after the lock-up period ended [8] - Silver Pharma-B (02591) experienced a decline of 14.32% as it was adjusted into the Hong Kong Stock Connect [9] - Sutech (02498) performed well, rising 5.23% after securing a major contract with FAW Toyota [10]

Group 1 - The Shenzhen Stock Exchange announced on December 8 that due to the adjustment of the Hang Seng Composite MidCap Index, the list of eligible securities for the Stock Connect program will be updated [1] - Four companies have been added to the Stock Connect program, effective from December 8, 2025: FWD Group (01828), Aux Group (02580), Sinopharm Group (02591), and Chery Automobile (09973) [1][3] Group 2 - The adjustment includes the addition of FWD Group, Aux Group, Sinopharm Group-B, and Chery Automobile to the Stock Connect program [3]

本文源自：财华网 【财华社讯】银诺医药-B(02591.HK)公布，根据上海证券交易所及深圳证券交易所分別发出的公告，公 司H股获纳入沪港通及深港通合资格证券名单，自2025年12月8日起生效。 ...

银诺医药-B(02591.HK)发布公告，根据上海证券交易所及深圳证券交易所分别发出的公告，本公司H股 (H股)获纳入沪港通及深港通(沪港通及深港通)合资格证券名单，自2025年12月8日起生效。 本文源自：金融界AI电报 ...

Core Viewpoint - The company, Silver Noble Pharmaceuticals-B (02591), has announced that its H-shares will be included in the eligible securities list for the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective from December 8, 2025, which is expected to enhance its investor base and trading liquidity [1] Group 1 - The inclusion of H-shares in the Stock Connect programs allows qualified investors from mainland China to directly invest in H-shares through the Shanghai and Shenzhen stock exchanges [1] - The board believes that this inclusion will further expand the company's investor base and increase the trading liquidity of H-shares [1] - The anticipated outcome is an enhancement of the investment value of H-shares and an improvement in the company's reputation in the capital markets [1]

格隆汇12月8日丨银诺医药-B(02591.HK)宣布，根据上海证券交易所及深圳证券交易所分别发出的公 告，公司H股获纳入沪港通及深港通合资格证券名单，自2025年12月8日起生效。 H股获纳入沪港通及深港通后，中国内地的合资格投资者可通过上海证券交易所及深圳证券交易所直接 投资H股。董事会认为，获纳入沪港通及深港通将进一步扩大公司的投资者基础及增加H股的交易流通 量，从而提升H股的投资价值及本公司於资本市场的声誉。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 自願性公告 獲納入滬港通及深港通證券名單 本公告乃由廣州銀諾醫藥集團股份有限公司（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，以向本公司股東（「股東」）及有意投資者提供有關本公司最新進 展的資料。 滬港通及深港通為股票市場交易互聯互通機制。上海證券交易所、深圳證券交易 所及香港聯合交易所有限公司已建立技術連接，使中國內地及中華人民共和國香 港特別行政區的投資者可以通過當地證券公司或經紀買賣在對方證券交易所上市 的合資格股票。 1 本公司謹此感謝股東及投資者一直以來的支持。本公司將繼續努力發展業務，為 股東創造價值。 股東及有意投資者於買賣本公司證券時，務請審慎行事。 承董事會命 廣州銀諾醫藥集團股份有限公司 ...